Our ability to identify variations of specific genomic regions that influence key aspects of recombinant protein production – otherwise known as Quantitative Trait Loci – heralds a new era in recombinant protein manufacture.
Thanks to our QTL technology, our genomic knowledge delivers an optimal manufacturing process for consistently high quality protein production. The process is customised for whatever the market requires – with patent protection included.
QTL technology uses breeding based on the world’s most diverse library of strains. It screens billions of progeny strains rather than hundreds and utilises the entire genome to bring genuine multi-parameter optimisation to recombinant protein manufacturing for the first time.
In the hands of our world-leading team of strain breeding and genomic experts, and with support from the Bill & Melinda Gates Foundation, QTL technology is delivering high quality, lower cost albumin to finally make key vaccines affordable to low and middle income countries.
By unlocking the full power of biology, QTL technology is also busily transforming a whole range of recombinant protein applications. These include premium biosimilars, supply chain proteins and discovery biologics.
Learn about the competitive advantages that a patent protected premium biosimilar process can deliver in terms of quality, consistency, efficiency, sustainability, simplicity, and pricing, all tailor-made to the needs of your chosen market.
Supply chain proteins
Discover how we unlock opportunities for recombinant proteins in carefully selected supply chains. Our bespoke strains enable the manufacture of proteins on a commercial scale that simply isn’t possible or viable for other technologies.
Find out how Phenotypeca can deliver bespoke manufacturing strains for your biologic therapeutic at the discovery stage to meet the timelines of your development program. All solutions are reliable, regulatory friendly, and commercially scalable.